Application note describes solid phase extraction (SPE) analysing the typically low levels of pharmaceutical drug metabolites found in biological fluids
Porvair Sciences has released an application note describing the operational benefits of using its innovative Microlute solid phase extraction (SPE) system for analysis of drugs and drug metabolites in biological fluids.
Based upon independent customer data, the application note describes how the SPE, prime wash and elution volumes stages of sample preparation are significantly reduced using the Microlute, allowing faster sample processing and increased method sensitivity.
The application note further shows that the individual well capacity of the low sorbent mass phases used in the Microlute are more than sufficient for the needs of analysing the typically low levels of pharmaceutical drug metabolites found in biological fluids.
Developed in conjunction with a leading pharmaceutical company, Porvair says the Microlute has become the benchmark for high throughput sample preparation across a range of applications.
The innovative design offers all the advantages of automated and high throughput SPE sample preparation in a convenient microplate format capable of rapidly processing 96 samples in one go repeatedly and precisely, it says.
Construction from a single piece of moulded high quality plastic means that Microlute will not bend or distort because individual SPE cartridges do not have to be repeatedly plugged in and out.
Using a proprietary sorbent slurry loading technique, Porvair has eliminated the channelling effects often limiting the performance of dry powder loaded SPE columns.
Each well on the Microlute has an individual drain spout ensuring 100% sample transfer and zero crossover contamination.
Working closely with the leading automated liquid handling companies has ensured that the Microlute delivers high productivity, trouble-free operation with all robotic sample handling and preparation systems, it says.
